ORIC Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.01. On average, analysts expect ORIC Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ORIC Pharmaceuticals Stock Up 0.9 %

Shares of ORIC traded up $0.05 during trading hours on Wednesday, reaching $5.71. The stock had a trading volume of 724,331 shares, compared to its average volume of 636,723. The firm has a 50-day moving average of $6.30 and a 200 day moving average of $8.28. The company has a market cap of $405.90 million, a P/E ratio of -3.14 and a beta of 1.38. ORIC Pharmaceuticals has a 52 week low of $3.90 and a 52 week high of $14.67.

Wall Street Analysts Forecast Growth

ORIC has been the subject of several research analyst reports. Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, January 14th. Finally, HC Wainwright restated a "buy" rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $18.86.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.